Adam Brufsky, MD, PhD, Angelo Di Leo, MD, PhD, and Prof. Miguel Martin, MD, PhD, discuss clinical trials and real-world studies assessing CDK 4/6 inhibitors for breast cancer in this CME activity titled, "Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: An Examination of the Evidence That Is Informing Real-World Practice." For the full presentation, downloadable Practice Aids, monograph, and complete CME information, and to apply for credit, please visit us at https://bit.ly/30x7qll. CME credit will be available until September 29, 2021.